BMS 986165

Drug Profile

BMS 986165

Alternative Names: BMS-986165

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antipsoriatics
  • Mechanism of Action Interferon type I inhibitors; Interleukin 12 inhibitors; Interleukin 23 inhibitors; PTK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Psoriasis
  • Preclinical Inflammatory bowel diseases; Systemic lupus erythematosus

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Psoriasis (In volunteers) in USA (PO) (NCT03004768)
  • 10 Nov 2016 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)
  • 10 Nov 2016 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top